LCMS Capabilities

GLP Bioanalytical LC-MS/MS Services

Alta has conducted a wide variety of bioanalytical studies in preclinical and clinical drug development. Alta specializes in rapid methods development and validation and has the capability for rapid sample analysis turnaround for all phases of drug discovery and development including early pharmacokinetic, toxicology/toxicokinetic and high volume clinical studies.

Sample Preparation Capabilities

• Sample control department designed to meet stringent FDA Good Laboratory Practice Standards
• 96-well sample prep methodologies (liquid-liquid, protein precipitation, and solid phase extraction
• OSHA compliant biohazard hoods and procedures for handling of infectious samples

Method Development and Validation

• Non-GLP bridging studies
• Feasibility studies on new compounds done at no charge with preliminary data available in 24-48 hours
• Development and validation < 4 weeks
• Start  of assay to QC data - 3 - 5 days
• Start of assay of QA data - 1 - 2 weeks
• Response to aberrant data < 24 hours

Validated Methods

The following  is a partial list of validated methods routinely performed by the LCMS Services group. For further information please contact Bob Bethem (VP of LCMS Services) or Dr. Jo Marie Smolec (Director of Business and Development).